Eisai Selects Medidata’s Clinical Data Studio to Enhance and Modernize
Clinical Trial Efficiency and Patient Experience
AI-enhanced solution will help Eisai accelerate data review andreconciliation by 80%
New York – July 25, 2024 – Medidata, a Dassault Systèmes brand and leading provider ofclinical trial solutions to the life sciences industry, today announced Eisai Inc. (“Eisai”), the U.S.
pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., as one of the first customers toharness its recently announced AI-driven Medidata Clinical Data Studio. Eisai Inc., will leveragethis innovative data experience to gain unprecedented control over its clinical data, enable theexecution of scalable and complex clinical trials, and enhance patient experience.
“We’ve included Medidata’s Clinical Data Studio in our clinical trial management platform given
its ability to break down data silos and seamlessly integrate into our current software stack,while maintaining quality and integrity across all data sources,” said Shobha Dhadda, Ph.D.
chief clinical science & operations officer, at Eisai. “Having a suite of technology solutions
capable of processing diverse clinical and patient data types provides increased efficiencies
without sacrificing quality or needing additional resources.”
Clinical Data Studio is powered by the Medidata Platform, the industry’s only unified platformthat centrally manages all data sources, improving data reliability across the entire clinical trialecosystem. By seamlessly integrating data from both Medidata sources, including Medidata
Rave EDC, and non-Medidata sources, such as labs or another electronic data capture system,
Clinical Data Studio streamlines the import process and enables automatic validation throughconfigured data transfer agreements. Utilizing AI, it mitigates challenges posed by disparate
data systems and offers up to 80 percent faster data review while providing a comprehensive
view of patient data that can be concurrently reviewed, visualized, and acted on.
“Through Clinical Data Studio, Eisai is enabling healthcare stakeholders to overcome thecomplexities of modern clinical trials and foster collaboration on cleaner, more actionable data,”
said Janet Butler, executive vice president, global head of sales, Medidata. “By delivering aunified AI-driven data management and analytics experience, we are enabling study teams toidentify potential data issues faster and gain a more accurate understanding of the patient.”
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to
support clinical trials. Celebrating 25 years of ground-breaking technological innovation acrossmore than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise,analytics-powered insights, and the largest patient-level historical clinical trial data set in theworld. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless,end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bringtherapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8,DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader byEverest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. We provide business and people withcollaborative virtual environments to imagine sustainable innovations. By creating virtual twin
experiences of the real world with our 3DEXPERIENCE platform and applications, ourcustomers can redefine the creation, production and life-cycle-management processes of theiroffer and thus have a meaningful impact to make the world more sustainable. The beauty of theExperience Economy is that it is a human-centered economy for the benefit of all –consumers,patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all
sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon,IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA,MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks
or registered trademarks of Dassault Systèmes, a European company (Societas Europaea)
incorporated under French law, and registered with the Versailles trade and companies registry
under number 322 306 440, or its subsidiaries in the United States and/or other countries. Allother trademarks are owned by their respective owners. Use of any Dassault Systèmes or its
subsidiaries trademarks is subject to their express written approval.
About Eisai Inc.
Eisai Inc., a human health care company, is the U.S. pharmaceutical subsidiary of Tokyo-based
Eisai Co., Ltd. headquartered in Nutley, N.J. Dedicated to oncology and neurology, its U.S.
operations include research & development; manufacturing; global supply & logistics; andcommercial activities. Learn more: https://us.eisai.com; Follow us on X and LinkedIn.
Contact:
Medidata PR
Medidata.PR@3ds.com
Analyst RelationsMedidata.AR@3ds.com